Recently published results from the prospective phase II trial (EXCITE), which included 76 rectal cancer patients who underwent R0 resection, indicate high heterogeneity according to the presence of KRAS and TP53 mutations in the comparison of biopsy samples obtained before neoadjuvant treatment (chemoradiation) and after treatment (resection material). The gene discussed is TP53; the disease is rectal cancer.